Physician profile
Michael Cantor
NPI 1851428197
$16,359.48
in general payments reported to CMS, 2019-2025
48 companies · $2,398 in 2025
The $2,398 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,153 · 2020: $1,389 · 2021: $2,298 · 2022: $2,316 · 2023: $3,225 · 2024: $2,581 · 2025: $2,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,203.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,167.16 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,851.94 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $1,422.92 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $753.54 | 2019-2025 | Entyvio |
| Novo Nordisk INC | $750.42 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $743.75 | 2019-2025 | Dificid, Recarbrio, Zerbaxa |
| Qol Medical, LLC | $543.07 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $402.53 | 2019-2025 | Tremfya, Stelara |
| Daiichi Sankyo INC. | $388.62 | 2019-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $361.31 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $357.58 | 2019-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $308.94 | 2019-2023 | Clenpiq |
| Exact Sciences Corporation | $292.19 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $264.55 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $263.02 | 2023-2024 | Quviviq |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cantor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.